Pyridine

Pyridine

SCHEMBL563923

I.c1ccncc1.c1ccncc1

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.90
NAPRT Q6XQN6 1/20 0.90
TDP1 Q9NUW8 1/20 0.90
NOTUM Q6P988 1/20 0.39
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2A6 P11509 1/20 0.32
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL10552175 1.00 TSHR (0.90) TSHRNAPRTTDP1NOTUMSLC6A2
Pyridine SCHEMBL69088 1.00
Pyridine SCHEMBL29517174 1.00 TSHR (0.90) TSHRNAPRTTDP1NOTUMSLC6A2
Pyridine SCHEMBL2323896 1.00
Pyridine SCHEMBL10752757 1.00
Pyridine SCHEMBL2323893 1.00 TSHR (0.90) TSHRNAPRTTDP1NOTUMSLC6A2
Pyridine SCHEMBL28726810 0.95 TSHR (0.82) TSHRNAPRTTDP1NOTUMSLC6A2
Pyridine SCHEMBL28479225 0.95 TSHR (0.82) TSHRNAPRTTDP1NOTUMSLC6A2
Pyridine SCHEMBL7997339 0.95
Pyridine SCHEMBL28510953 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110483430-A A kind of preparation method of Isoxazole derivative SHANGHAI INST TECH 2019-11-22 CN claimed
CN-110483400-A A kind of preparation method of pyrazole derivatives SHANGHAI INST TECH 2019-11-22 CN claimed
CN-115397824-B Process for preparing COT inhibitor compounds 吉利德科学公司 2024-10-22 CN disclosed
CN-118239931-A As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-06-25 CN disclosed
CN-116148336-A Mass spectrometry method for measuring unsaturated fatty acid isomer 中国科学院上海有机化学研究所 2023-05-23 CN disclosed
CN-116148336-A Mass spectrometry method for measuring unsaturated fatty acid isomer 中国科学院上海有机化学研究所 2023-05-23 CN disclosed
CN-110483430-B Preparation method of isoxazole derivative 上海应用技术大学 2023-02-10 CN disclosed
CN-114269432-A As P2X3Aminoquinazoline derivatives as inhibitors 奇斯药制品公司 2022-04-01 CN disclosed
CN-110483400-A A kind of preparation method of pyrazole derivatives SHANGHAI INST TECH 2019-11-22 CN disclosed
CN-110483430-A A kind of preparation method of Isoxazole derivative SHANGHAI INST TECH 2019-11-22 CN disclosed
US-20120238563-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES CID-NUNEZ JOSE MARIA (ES) 2012-09-20 US disclosed
US-20120035170-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES NUNEZ JOSE MARIA (ES) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035170-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES HTR2C, HTR2A, HTR1A TSHR 499/4885NAPRT 1245/4885TDP1 2554/4885
US-20120238563-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES HTR2C, HTR2A, HTR1A TSHR 499/4885NAPRT 1245/4885TDP1 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.